Bristol Current Ratio

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Report: 6th of August 2020  

Bristol Myers current ratio fundamental analysis lookup allows you to check this and other indicators for Bristol Myers Squibb or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please continue to Equity Screeners to view more equity screening tools

Search Current Ratio

 
Refresh
Bristol Myers Net Current Assets as percentage of Total Assets are fairly stable at the moment as compared to the past year. Bristol Myers reported Net Current Assets as percentage of Total Assets of 8.50 in 2019. Assets Non Current is likely to grow to about 108.5 B in 2020, whereas Current Ratio is likely to drop 1.54 in 2020.

Bristol Current Ratio Analysis

Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
 2017 2018 2019 2020 (projected)
Receivables5.09 B5.35 B7.68 B8.29 B
Inventories1.17 B1.2 B4.29 B4.63 B
Current Ratio 
 = 
Current Asset 
Current Liabilities 
More About Current Ratio | All Equity Analysis

Current Bristol Myers Squibb Current Ratio

1.66 X

Bristol Current Ratio Over Time Pattern

 Bristol Myers Current Ratio 
      Timeline 

About Current Ratio

Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Compare to competition

Bristol Myers Current Ratio Related Assessment

  Net Loss Income from Discontinued Operations

In accordance with the recently published financial statements Bristol Myers Squibb has Current Ratio of 1.66 times. This is 42.96% lower than that of the Healthcare sector and significantly higher than that of Drug Manufacturers?General industry. The current ratio for all United States stocks is 23.15% higher than that of the company.

Did you try this?

Run Positions Ratings Now

   

Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Bristol MyersCurrent Valuation Drivers

2014201520162017201820192020 (projected)
Revenue Per Employee635.16 K662.4 K774.96 K876.62 K968.28 K871.5 K774.9 K
Average Assets33.53 B32.27 B33.04 B33.47 B33.61 B69.34 B57.53 B
Earnings before Tax2.36 B2.01 B5.87 B5.16 B5.94 B4.95 B4.63 B
Average Equity15.2 B15 B15.27 B13.91 B13.2 B25.13 B22.34 B
Enterprise Value100.73 B118.06 B101.06 B104.1 B86.74 B99.05 B100.45 B
Free Cash Flow2.62 B1.28 B1.84 B4.22 B4.99 B7.23 B6.09 B
Invested Capital18.77 B19.73 B19.08 B18.46 B17.14 B59.57 B64.27 B
Tangible Asset Value24.97 B23.45 B25.45 B25.48 B27.36 B43.49 B38.07 B
Working Capital6.15 B2.4 B4.86 B5.29 B7.06 B11.05 B9.3 B
Interest Coverage12.7610.2727.7218.4327.979.019.25
Calculated Tax Rate14.7821.4723.881.017.1130.4526.35
PPandE Turnover3.313.533.754.134.164.54.64
Receivables Turnover7.396.045.44.574.324.015.96
Inventory Turnover2.572.814.025.045.552.943.12
Operating Margin16.3211.4123.8317.3922.6922.6223.88
Return on Investment11.228.6621.1216.9624.929.8815.4
Cash Flow Per Share1.91.11.713.253.663.583.03
Revenue to Assets0.420.470.520.580.620.20.21
Quick Ratio1.150.931.171.241.341.261.13
Book Value per Share8.958.559.687.178.631.6734.17
Current Ratio1.521.731.31.551.661.61.54
Debt to Equity Ratio1.541.261.211.851.491.521.57
Dividend Yield0.0330.0250.0220.020.0310.0260.0269
EBITDA Margin0.140.220.180.320.290.260.25

Bristol Fundamentals

About Bristol Myers Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol Myers using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way. Please read more on our fundamental analysis page.
 2017 2018 2019 2020 (projected)
Receivables5.09 B5.35 B7.68 B8.29 B
Inventories1.17 B1.2 B4.29 B4.63 B


 
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page